Pharmacoflash 6 : Biologics

15:00 • 644 • Both CD4 and CD8 anti-CD19 CAR T-cells are involved in target depletion and clinical efficacy in B-cell malignancies – a joint CD4 and CD8 CAR T-cell kinetic-time-to-event framework > D. David TERNANT 15:06 • 255 • Detecting immunogenicity to infliximab or adalimumab in patients using machine learning techniques > D. David TERNANT 15:18 • 209 • Population Pharmacokinetic–Pharmacodynamic Modelling of Secukinumab in Real-World Psoriasis Patients to Support Model-Informed Precision Dosing > A. Anke Eylenbosch 15:24 • 600 • Towards infliximab personalized therapy in the IBD induction period: POPPK models external evaluation > A. ANNA SAGUER MARGALEF 15:30 • 494 • Bridging the Gap Between Chemiluminescence Immunoassay and LC-MS/MS for Infliximab Monitoring: Method Validation and Clinical Comparability Study > Y. Ying Xia 15:36 • 701 • TNF-a as a Candidate Toxicity Biomarker for Obinutuzumab-induced Thrombocytopenia: A Pilot Multi-Omics Study with Experimental Validation > M. Ma Yi